Recent developments in the health sector highlight diverse changes from drug pricing initiatives by Bristol Myers and Pfizer ...

Pfizer PFE has committed significant resources for the development of treatments in the fields of oncology, internal medicine, immunology, inflammation and vaccines. Over the past decade, Pfizer has ...

Sino Biopharma will acquire LaNova Medicines, which has licensed cancer drugs for Merck and AstraZeneca, for $951 million.

If your physician prescribes a new branded drug, though, you and your insurance company have few options. Patent-protected exclusivity is the reason pharmaceutical stocks are known for delivering ...

Pfizer is navigating challenges in the post-COVID era, emphasizing innovation, oncology, and AI in drug development for potential growth. Learn more on PFE stock here.

Pfizer Inc. (NYSE: PFE) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of ...

Pfizer has also sought regulatory approvals for the drug in Australia, India and the UK, among others. Leerink Partners in October estimated the drug's 2030 sales at $2.2 billion.

Pfizer says its strategy of relying on internal innovation is bearing fruit, with a series of new drug approvals coming in the second quarter and drugs from recent deals helping drive revenue ...

The government’s top vaccine official working under Health Secretary Robert F. Kennedy Jr. recently restricted the approval of two COVID-19 vaccines, disregarding recommendations from government ...

Pfizer/BioNTech, Moderna, ... FDA Plans Fast Approvals of Updated COVID-19 Variant Vaccines ... [Food and Drug Administration] and CDC ...

Pfizer Inc <PFE.N> said on Thursday that six of its drugs could be approved in Japan this year, including the cancer drug Sutent.